NCT04768426View on ClinicalTrials.gov

Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 3, 2021

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions
Triple Negative Breast CancerBreast Cancer
Interventions
DRUG

Capecitabine

1000 mg/m2 administered on Days 1 to 14 of 21-day treatment cycles, for 8 cycles.

Trial Locations (1)

94304

RECRUITING

Stanford University, Stanford

All Listed Sponsors
lead

Stanford University

OTHER